nigripalpus population in the PET, São Paulo, Brazil. Parque Ecológico do Tietê ... was read at 405 nm wavelength in a 230S Organon Teknika tm plate reader. The negative control (eight Cx. nigripalpus ...

Organon & Co. (NYSE:OGN), a prominent player in the healthcare sector, has been garnering attention from analysts due to its diverse product portfolio and strategic market positioning. The company ...

We recently published a list of These 10 Firms Are On Fire Today. In this article, we are going to take a look at where Organon & Co.’s (NYSE:OGN) stands against other stocks that surged yesterday.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the ...

INCHEON, Korea & JERSEY CITY, N.J., May 27, 2025--Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April ...

Português (Brasil) ... (OTC: BNPQY) Exane adjusted its outlook on Organon & Co. (NYSE: OGN), reducing the price target to $16 from the previous $29, while retaining an Outperform rating on the stock.

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks ...

Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the Company’s possible violations of ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.